Overview

"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy. Lopinavir/ritonavir pharmacokinetics might prevent resistance development in patients who experience virological rebound after single-drug simplification.

Phase:

Phase 4

Details

Lead Sponsor:

Arribas, Jose R., M.D.

Collaborators:

Abbott
Pulido, Federico, M.D.

Treatments:

Lopinavir
Ritonavir